Cerebrolysin: what the published research shows

Cerebrolysin is a multimodal neuropeptide preparation manufactured from porcine brain-derived peptides and free amino acids; the published literature also refers to it as a neurotrophic peptide preparation and, in older work, as a cerebrolysin peptide complex. The evidence block used for this page does not supply a sequence, molecular formula, or molecular weight for the preparation, so none is stated here. It is handled in the research literature as a parenteral peptide-based agent rather than a single defined small molecule.

The mechanistic work indexed here centres on neurotrophic and neuroplasticity signalling together with cerebrovascular endothelial barrier function, with the endothelial permeability studies focused on tight-junction protein cargo carried by exosomes released from cerebral endothelial cells.

Research Studies

Cerebrolysin and post-thrombectomy recovery in extended-window large-vessel occlusion

A multicentre randomized clinical trial is evaluating whether Cerebrolysin given after successful extended-window endovascular thrombectomy reduces brain tissue injury and supports recovery [1]. The rationale given is that thrombectomy can benefit selected patients treated 6 to 24 hours after onset, yet some remain disabled even after the blocked artery is reopened, with ongoing injury to brain tissue, small vessels, and the blood-brain barrier proposed as a contributor [1]. The population under study is acute ischemic stroke patients with large-artery occlusion who have undergone successful extended-window thrombectomy [1].

Cerebrolysin and basilar artery occlusion after mechanical thrombectomy

A case report described a 67-year-old woman with multiple vascular risk factors who presented with acute basilar artery occlusion and was treated with intravenous thrombolysis followed by successful mechanical thrombectomy (TICI grade 3), with adjunctive Cerebrolysin administered subsequently [2]. Rapid neurological improvement was observed within 24 hours, with NIHSS decreasing from 7 to 2, followed by complete neurological recovery (NIHSS 0) [2]. This is a single-patient observation in a posterior-circulation stroke population and does not establish efficacy.

Cerebrolysin and Wernicke's aphasia alongside speech-language therapy

A second case report described a 38-year-old female lawyer who developed acute Wernicke's aphasia and right-sided hemiparesis after ischemic stroke and, despite timely thrombolysis and mechanical thrombectomy, had significant neurological deficits [3]. Early multidisciplinary rehabilitation combined with a 10-day course of Cerebrolysin was administered [3]. Post-stroke aphasia is reported to affect approximately one-third of stroke survivors, and speech-language therapy remains the standard of care in that setting [3].

Cerebrolysin and cerebral endothelial permeability in vitro

Using an in vitro endothelial permeability assay, one study tested whether exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) act on dysfunctional cerebral endothelial cells [4]. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes from untreated cells (Naïve-Exos), with Cerebro-Exos highly enriched in metabolic and tight junction related proteins [4]. Cerebro-Exos had a superior effect to Naïve-Exos on restoring endothelial cell integrity impaired by fibrin and tissue plasminogen activator [4]. This is cell-culture work, not an in vivo finding.

Cerebrolysin combined with speech therapy in nonfluent aphasia

A conference abstract reports a meta-analysis of the effect of Cerebrolysin combined with speech therapy on nonfluent aphasia recovery after ischemic stroke [6]. The evidence block provides the abstract title and identifier only, without effect estimates, so no pooled result is reported here.

Cerebrolysin as an add-on in virtual reality neurorehabilitation

A second conference abstract addresses virtual reality neurorehabilitation in acute stroke patients and the add-on effect of Cerebrolysin [7]. As with the aphasia meta-analysis, only the title and identifier are available in the evidence block, and no outcome values are stated.

Cerebrolysin and 12-month functional outcomes after endovascular thrombectomy

A third conference abstract reports 12-month functional outcomes in a propensity-matched cohort of stroke patients who received Cerebrolysin after endovascular thrombectomy [8]. The evidence block supplies the title and identifier only; no numerical results are reproduced here.

Cerebrolysin and very early short-course administration after tenecteplase and thrombectomy

A case report described an 88-year-old woman treated with a very early short course of Cerebrolysin after tenecteplase and mechanical thrombectomy [9]. The report notes that despite high recanalization rates with mechanical thrombectomy, large-vessel occlusion stroke results in death or dependency in over half of patients, and that Cerebrolysin may attenuate ischemia-reperfusion injury and support early neurorehabilitation [9]. This is a single-patient observation.

Retracted and withdrawn Cerebrolysin studies

Several Cerebrolysin papers in the indexed literature carry retraction notices. A retraction note concerns a study of Cerebrolysin attenuating exacerbation of neuropathic pain, blood-spinal cord barrier breakdown, and cord pathology following chronic intoxication with engineered silver, copper, or aluminium nanoparticles of 50-60 nm [5]. Further retraction notices concern a regional comparison of the neurogenic effects of CNTF-derived peptides and Cerebrolysin in AβPP transgenic mice [10], a study of timed release of Cerebrolysin using drug-loaded titanate nanospheres in a Parkinson's disease model [11], and a study of neurotrophic effects of Cerebrolysin in the Mecp2^308/Y transgenic model of Rett syndrome [12]. These notices are recorded here because they form part of the published record; the underlying findings should not be treated as established.

What the evidence does and does not cover

Two points should be stated plainly. First, the endothelial permeability findings are in vitro only, performed in cerebral endothelial cell cultures, and no in vivo confirmation is supplied in the evidence block [4]. Second, the human recovery observations in the case reports are single-patient descriptions in specific stroke populations and cannot be generalised to a broader patient group [2][3][9]. The randomized trial listed here is described as ongoing, so no efficacy conclusion can be drawn from it at this time [1].

If you are reading this for personal health reasons

This material is sold for laboratory research use only. We do not provide dosing information or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy — https://clinicaltrials.gov/study/NCT06339411
• [2] Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report — https://europepmc.org/article/PMC/PMC13474398
• [3] Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report — https://europepmc.org/article/PMC/PMC13474394
• [4] Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability — https://europepmc.org/article/PMC/PMC13205112
• [5] Retraction Note: Cerebrolysin Attenuates Exacerbation of Neuropathic Pain, Blood-Spinal Cord Barrier Breakdown and Cord Pathology Following Chronic Intoxication of Engineered Ag, Cu or Al (50-60 nm) Nanoparticles — https://europepmc.org/article/PMC/PMC13179879
• [6] ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE — https://europepmc.org/article/PMC/PMC13146077
• [7] ABSTRACT NUMBER: ESOC2026A822 VIRTUAL REALITY NEUROREHABILITATION IN ACUTE STROKE PATIENTS AND THE ADD-ON EFFECT OF CEREBROLYSIN — https://europepmc.org/article/PMC/PMC13145624
• [8] ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT — https://europepmc.org/article/PMC/PMC13146562
• [9] Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report — https://pubmed.ncbi.nlm.nih.gov/42666484/
• [10] Retraction: Regional Comparison of the Neurogenic Effects of CNTF-Derived Peptides and Cerebrolysin in AβPP Transgenic Mice — https://pubmed.ncbi.nlm.nih.gov/42015030/
• [11] Retraction Note to: Timed Release of Cerebrolysin Using Drug-Loaded Titanate Nanospheres Reduces Brain Pathology and Improves Behavioral Functions in Parkinson's Disease — https://pubmed.ncbi.nlm.nih.gov/41920231/
• [12] Retraction Note: Neurotrophic effects of Cerebrolysin in the Mecp2^308/Y transgenic model of Rett syndrome — https://pubmed.ncbi.nlm.nih.gov/41874695/